Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.

被引：0
|
作者：
Gattermann, Norbert [1 ]
Sanz, Guillermo F. [2 ]
Giagounidis, Aristoteles [3 ]
Seymour, John F. [4 ]
Fenaux, Pierre [5 ]
Santini, Valeria [6 ]
Mufti, Ghulam J. [7 ]
Muus, Petra [8 ]
Ramos, Fernando [9 ,10 ]
Lucy, Lela M. [11 ]
Beach, C. L. [11 ]
Silverman, Lewis R. [12 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol, Dusseldorf, Germany
[2] Hosp Univ La Fe, Dept Hematol, Valencia, Spain
[3] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[6] UF Ematol AOU Careggi, Florence, Italy
[7] Kings Coll Hosp London, London, England
[8] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands
[9] Hosp Leon, Leon, Spain
[10] IBIOMED, Leon, Spain
[11] Celgene Corp, Overland Pk, KS USA
[12] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1643 / 1644
页数：2
相关论文
共 50 条
  • [21] Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS
    Gore, S.
    Fenaux, P.
    Santini, V.
    Bennett, J. M.
    Silverman, L. R.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Swern, A. S.
    Beach, C. L.
    List, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)
    Santini, Valeria
    Fenaux, Pierre
    Mufti, Ghularn J.
    Hellstrom-Lindberg, Eva
    Silverman, Lewis B.
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 583 - 584
  • [23] Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Petrone, Michael E.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2018, 132
  • [24] Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 49 - 56
  • [25] PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROMA PHASE II, OPEN-LABEL STUDY.
    Laille, E.
    Xiao, Z.
    Du, X.
    Dong, Q.
    Songer, S.
    Beach, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81
  • [26] Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 13
  • [27] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [28] Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)
    Watts, Justin
    Sekeres, Mikkael
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolai
    Fram, Robert
    Zhao, Dan
    Friedlander, Sharon
    Galinsky, Kevin
    Faller, Douglas
    Ades, Lionel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S347 - S348
  • [29] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Cook, Rachel
    Jacoby, Meagan
    Nowak, Daniel
    Chyla, Brenda
    Zhou, Ying
    Ku, Grace
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [30] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
12345